Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Final O'Neill Review Suggests Supra-National AMR Body & Pharma Levy

Executive Summary

Antimicrobial Resistance (AMR) is a huge economic and security threat necessitating immediate coordinated action and pooled funding by a global coalition of governments, institutions, companies and NGOs, Jim O'Neill says in his review's final report on the topic, which outlines a menu of options for accomplishing that – including a levy on the pharma sector – and says a supra-national entity will also be needed to tackle AMR.


Related Content

Wellcome Trust Makes AMR Strategic Priority After Funding O'Neill Review
Jim O’Neill Is “Free For Global AMR Role” After Leaving UK Government
Jim O’Neill Is “Free For Global AMR Role” After Leaving UK Government